In this featured commentary, Thierry Van Nieuwenhove, CEO of Quotient Sciences, discusses the role of clinical trials and manufacturing in the UK.
In light of Merck and AstraZeneca UK investment pull back, Manufacturing Chemist explores the role of CDMOs in driving agility, innovation and technical expertise could redefine how and where drugs are made.
With these Big Pharma pausing UK investments, contract development and manufacturing organisations (CDMOs) are positioning their agility and technical depth to fill the gap.
Quotient Sciences CEO Thierry Van Nieuwenhove says clinical trial bottlenecks have been a drag, but notes approvals are now moving faster—around 41 days for initial MHRA reviews—strengthening the case for UK-based development and manufacturing.
Continue reading the full article on Manufacturing Chemist.